Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E33.43 EPS (ttm)12.38 Insider Own0.10% Shs Outstand234.61M Perf Week-4.13%
Market Cap97.08B Forward P/E20.81 EPS next Y19.88 Insider Trans-22.83% Shs Float234.43M Perf Month0.25%
Income2.93B PEG1.85 EPS next Q3.93 Inst Own92.40% Short Float1.53% Perf Quarter20.93%
Sales9.70B P/S10.01 EPS this Y58.40% Inst Trans-0.56% Short Ratio1.85 Perf Half Y25.09%
Book/sh45.90 P/B9.02 EPS next Y16.75% ROA22.10% Target Price474.98 Perf Year33.58%
Cash/sh7.87 P/C52.61 EPS next 5Y18.03% ROE29.40% 52W Range272.02 - 480.18 Perf YTD21.91%
Dividend- P/FCF36.57 EPS past 5Y29.90% ROI26.20% 52W High-13.82% Beta1.03
Dividend %- Quick Ratio1.70 Sales past 5Y17.30% Gross Margin87.90% 52W Low52.12% ATR12.52
Employees7550 Current Ratio2.10 Sales Q/Q34.30% Oper. Margin40.40% RSI (14)45.22 Volatility2.67% 2.64%
OptionableYes Debt/Eq0.05 EPS Q/Q94.80% Profit Margin30.20% Rel Volume1.40 Prev Close422.24
ShortableYes LT Debt/Eq0.05 EarningsApr 22 BMO Payout0.00% Avg Volume1.94M Price413.81
Recom2.00 SMA20-3.34% SMA502.22% SMA20019.43% Volume2,709,675 Change-2.00%
Mar-23-15Downgrade Stifel Buy → Hold
Feb-02-15Reiterated Argus Buy $385 → $440
Jan-30-15Reiterated RBC Capital Mkts Outperform $400 → $445
Jan-30-15Reiterated Deutsche Bank Buy $430 → $460
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Mar-19-14Reiterated Stifel Buy $360 → $376
Mar-07-14Reiterated Barclays Overweight $325 → $352
Mar-03-14Reiterated Stifel Buy $330 → $360
Jan-30-14Reiterated UBS Neutral $300 → $310
Jan-30-14Reiterated Brean Capital Buy $293 → $377
Jan-30-14Reiterated Argus Buy $310 → $360
Jan-28-14Reiterated Deutsche Bank Buy $340 → $415
Jan-27-14Reiterated Canaccord Genuity Buy $291 → $355
Jan-16-14Reiterated Stifel Buy $296 → $321
Jan-10-14Reiterated Barclays Overweight $285 → $325
Dec-20-13Reiterated RBC Capital Mkts Outperform $275 → $325
Apr-01-15 05:42PM  Health Stocks Lead The Pack In Q1; Are They Fading? at Investor's Business Daily
04:01PM  Biogen to Report First Quarter 2015 Financial Results on April 24, 2015 Business Wire
03:12PM  Biotech Stock Roundup: Horizon to Buy Hyperion, Conatus Up on Liver Disease Data - Analyst Blog
11:03AM  Biogen Idec: Survey Says at Barrons.com
09:20AM  Barclays Raises Biogen Forecasts After Physician Survey
06:01AM  Soaring biotech stocks are looking a bit sickly at MarketWatch
Mar-31-15 03:49PM  Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog
02:45PM  On the move: New hires and job transitions in the local life science industry at bizjournals.com
11:57AM  Health-care hedge fund Orbimed's top picks at MarketWatch
10:54AM  Biotech: Why It's Not a Bubble at Barrons.com
Mar-30-15 06:55PM  Cramer: The best places for you to put new money at CNBC
06:09PM  Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog
06:00PM  Making Money With Charles Payne: 03/30/15 at Fox Business
03:07PM  Why Gilead Stock Could Rise
02:20PM  Retail Investors: Buyers in all Ten Sectors Last Week
11:31AM  Bulls, Bears Squaring Off At Biogen
11:12AM  Teva, Horizon Snap Up Orphan-Disease Drugs at Investor's Business Daily
02:00AM  Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab Business Wire
Mar-27-15 07:26PM  Biotech bubble popped, time to buy again? at Fortune
06:40PM  Cramer: 4 horsemen of biotech & semis are back at CNBC
04:18PM  BIOGEN INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
03:14PM  Biotech bubble may just be an optical illusion at MarketWatch
01:30PM  Here's everything you need to know about the biotech bubble at bizjournals.com
01:16PM  Which 4 Big Drugmakers Have Rising Estimates? at Investor's Business Daily
11:19AM  The biotech sector looks an awful lot like a bubble
10:37AM  Biotech: 'Unprecedented Times,' Not a Bubble at Barrons.com
08:35AM  RBC Has 4 Biotech Stocks to Buy After Massive Pullback at 24/7 Wall St.
07:00AM  European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA (Daclizumab High-Yield Process) for Treatment of MS Business Wire
Mar-26-15 02:12PM  Biotech Battering Renews Bubble Debate Over Sector's Pricey Stocks at Forbes
12:53PM  Biogen Shares Set for Another Pullback at Barrons.com
12:32PM  What You Need To Know About This Boom: Our Q&A With A Biotech Expert
12:12PM  Biotech Stock Selloff: Is It Justified? at Investor's Business Daily
12:02PM  Healthcare Hedge Fund Orbimeds Top Picks and New Move at Insider Monkey
10:09AM  "It's a boom, not a bubble" -- except in biotech, Lindzon says
09:47AM  The Biotech Selloff: It's Déjà Vu All Over Again at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases
08:22AM  One analyst is convinced the biotech stock plunge is 'misguided'
07:25AM  7 Companies That Seriously Should Split Their Stocks at 24/7 Wall St.
Mar-25-15 06:55PM  Can Biogen Change How We View Alzheimer's Disease? at Investopedia
05:11PM  Dismal Data Drops Dow 300 Points, Nasdaq Crumbles as Biotech Tumbles at Barrons.com
04:44PM  Stock Market Sell-Off: Biotechs, Chips Hardest Hit at Investor's Business Daily
03:21PM  Worries Bubble About Biotech at Barrons.com
02:55PM  This year's sell off in biotech stocks is starting to look a lot like last year's sell off in biotech stocks
02:46PM  Biotechs On Track For Worst Week In A Year at Investor's Business Daily
01:20PM  Getting it Right (and Wrong) With Leveraged Biotech ETFs ETF Trends
12:25PM  Biogen data reignites debate over Alzheimer's cause as investors back off (Video) at bizjournals.com
12:05PM  Losses Build For Stocks; Papa Murphy's Bucks Weakness at Investor's Business Daily
11:50AM  Biotech's Rally Fuels Bubble Fears at The Wall Street Journal
11:10AM  4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
10:28AM  Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog
09:30AM  The Zacks Analyst Blog Highlights: HSBC Holdings, Goldman Sachs, Acorda Therapeutics, Biogen Idec and Ross Stores - Press Releases
09:15AM  Major Biotech Is So-So for Short Sellers at 24/7 Wall St.
Mar-24-15 11:52PM  [$$] Biotechs Rally Fuels Bubble Fears at The Wall Street Journal
09:52PM  Eisai Soars On Alzheimer's Drug With Biogen: How Much Is BIIB037 Worth? at Barrons.com
06:40PM  Is It Time to Consider Selling Biogen? at Investopedia
02:51PM  Stock Market Further Weakens; Nasdaq Dips Below 5000 at Investor's Business Daily
10:29AM  Will pharma rally continue?
10:10AM  Stock Market News for March 24, 2015 - Market News
09:45AM  2 Stocks to Beat the Dollar's Volatile Run - Analyst Blog
07:43AM  Why Intercept Might Be A Better Bet Than Biogen Right Now
12:22AM  Overheard: Biogen Boost Cant Cure Genworth at The Wall Street Journal
12:01AM  New Alzheimer's Research Throws Cold Water on Biogen's Recent Breakthrough
Mar-23-15 05:07PM  Biogen Gains on Positive Alzheimer's Drug Interim Results - Analyst Blog
05:01PM  Red flags for biotech
04:00PM  STOCKS SLIP: Here's what you need to know
03:37PM  Signs of Froth in the Biotech Sector
02:37PM  Biogen Boost Can't Cure Genworth -- Overheard at The Wall Street Journal
02:21PM  Weekly Options Outlook: Bulls Leave Money On The Table Despite A Week-End Win
02:18PM  Halftime's hottest trades today: PFE, SPLS, BIIB, & UAL
02:14PM  Biogen downgrade, Pfizer rises
01:30PM  Barrons 400 Index, ETF Make Some Changes ETF Trends
01:10PM  Biogen: The Day After
01:08PM  Biotech Boost Can't Cure Genworth at The Wall Street Journal
12:52PM  Call of the Day: Downgrading Biogen
12:31PM  Analyst says Biogen has been 'wild-fun,' but it's time to take a break
12:13PM  ICYMI: Pharmaceutical Stocks Are Moving Big On Monday
11:53AM  Genworth: A Biogen Play? at Barrons.com
11:38AM  3 Biotech ETFs in Focus as Biogen Soars - ETF News And Commentary
11:05AM  Biotech stocks on pace to snap 8-day win streak as warnings abound at MarketWatch
10:34AM  Genworth, Tenet top S&P 500 gainers; Vertex down on drug trial at MarketWatch
10:31AM  Genworth Financial (GNW) Stock Rising Today Following Raymond James Upgrade at TheStreet
10:22AM  Stocks trade near highs; dollar, oil eyed at CNBC
09:25AM  Biogen Idec (BIIB) Worth Watching: Stock Rises 9.8% - Tale of the Tape
09:22AM  Buy Genworth to Bet on Biogen Dementia Drug, Raymond James Says at Bloomberg
09:13AM  Monsanto weed-killer cancer risk; Gilead's drug warning; Tenet jumps on deals
09:08AM  Morning Movers: Gilead Drops on Heart Patient Warning; Biogen Falls on Downgrade at Barrons.com
08:50AM  Cramer's stocks to watch: Amazing biotech
08:49AM  Dollar wont crash the S&P 500 as long as the Fed stays friendly at MarketWatch
08:46AM  Stifel Downgrades Biogen Amid Concerns Of Lack Of Upcoming Data, Overvaluation
08:27AM  Biogen Drops Idec From Name at The Wall Street Journal
08:25AM  Top Analyst Upgrades and Downgrades: AK Steel, Carnival, EMC, Kinder Morgan, NVIDIA, Staples, Tyco and More at 24/7 Wall St.
08:25AM  Wall Street uneasy ahead of busy data week at CNBC
08:16AM  Early movers: Biogen, Staples, Pfizer & more at CNBC
08:12AM  Wall Street eyes Fed hints; Monsanto controversy; Starbucks' reversal
08:04AM  Market record trifecta
08:03AM  Analysts' Actions: Biogen Idec, Darden, Nvidia and More TheStreet
07:41AM  Biogen's stock falls on first day with new name after analyst downgrade at MarketWatch
06:00AM  Biogen Idec Becomes Biogen Business Wire
01:14AM  Exclusive: Biogen shortens name, expands ambitions in Alzheimer's, ALS
Mar-22-15 08:48PM  Eisai Jumps Most on Record on Successful Alzheimers Drug Data at Bloomberg
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company's products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer's disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 27Sale430.12430184,9528,574Mar 30 04:13 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Option Exercise65.855,066333,57137,577Mar 26 04:31 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Sale449.0612,0105,393,21125,567Mar 26 04:31 PM
Rowinsky Eric KDirectorMar 20Option Exercise59.8211,667697,92022,977Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 20Sale475.0011,6675,541,82511,310Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 19Option Exercise59.822,333139,56013,643Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 19Sale436.142,3331,017,50811,310Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 17Option Exercise59.824,667279,18015,977Mar 18 05:03 PM
Rowinsky Eric KDirectorMar 17Sale425.454,6671,985,58911,310Mar 18 05:03 PM
DiPietro KennethEVP Human ResourcesMar 16Sale415.46803333,6140Mar 17 08:10 PM
SCANGOS GEORGE AChief Executive OfficerMar 13Sale412.69537221,61345,176Mar 16 08:39 PM
SHERWIN STEPHEN ADirectorMar 10Option Exercise59.826,000358,92010,150Mar 11 04:17 PM
PANGIA ROBERT WDirectorMar 10Option Exercise47.713,625172,95417,998Mar 11 04:13 PM
PANGIA ROBERT WDirectorMar 10Sale413.403,6251,498,57814,873Mar 11 04:13 PM
SHERWIN STEPHEN ADirectorMar 10Sale409.676,0002,458,0204,150Mar 11 04:17 PM
Rowinsky Eric KDirectorMar 09Option Exercise59.824,666279,12015,976Mar 11 04:15 PM
Rowinsky Eric KDirectorMar 09Sale417.234,6661,946,79511,310Mar 11 04:15 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 02Sale409.493,1741,299,7159,004Mar 03 04:44 PM
SCANGOS GEORGE AChief Executive OfficerMar 02Sale410.67825338,80345,713Mar 03 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 19Sale401.04537215,35846,538Feb 20 04:28 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale389.11825321,01647,075Feb 18 04:45 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 17Sale389.112,128828,0264,321Feb 18 04:41 PM
DiPietro KennethEVP Human ResourcesFeb 17Sale389.111,188462,263803Feb 18 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 17Sale389.11418162,64815,004Feb 18 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.0015,599045,547Feb 17 09:32 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.0047101,450Feb 17 09:16 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.003,63407,152Feb 17 08:54 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,20101,318Feb 17 08:50 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.001,605015,805Feb 17 08:47 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.004,299022,960Feb 17 08:44 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,738033,214Feb 17 08:40 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.005,200016,481Feb 17 08:37 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.003,769028,634Feb 17 08:34 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,76402,706Feb 17 08:30 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.003,60108,771Feb 17 08:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833043,148Feb 11 04:25 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 10Sale398.111,143455,03914,574Feb 11 04:26 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691022,194Feb 10 05:06 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691032,744Feb 10 05:07 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82407,088Feb 10 05:08 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,398Feb 10 05:11 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270029,255Feb 11 04:25 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909027,716Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Sale398.05856340,73114,574Feb 10 05:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498024,625Feb 10 05:12 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468014,542Feb 10 05:14 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277015,851Feb 10 05:11 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70505,802Feb 10 05:10 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,63606,147Feb 10 05:08 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023029,590Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191018,646Feb 10 05:06 PM
DiPietro KennethEVP Human ResourcesFeb 02Sale389.031,656644,2340Feb 03 06:35 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 02 07:46 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,157013,133Feb 02 07:43 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,15705,157Feb 02 07:40 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM
Holtzman Steven HEVP Corporate DevelopmentApr 17Sale291.001,221355,3116,970Apr 21 05:07 PM